We couldn’t identify any result where this feature was present along with the other limiting features. Moreover, the description revealed unsupported” could very well fit in.
Thus, we put this forward for a discussion with our client.
has ruled in favour of Regeneron Pharmaceuticals, Inc and Sanofi, finding that Amgen’s asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on a lack of enablement.“[This] decision by the US District Court for the District of , Executive Vice President, General Counsel and Secretary, Regeneron.
“Praluent was developed using Regeneron’s proprietary science and technology and the judge has confirmed our position by issuing this ruling.”This ruling has overturned portions of an earlier jury verdict upholding the validity of three claims.
Now, while conducting invalidation searches, most would usually jump into looking for a prior art right away, i.e. But in our experience, we have found that it is better to do the homework right before jumping on searching.